Abstract
Bedtime inhalation of a novel muscarinic M3 receptor antagonist markedly lowered ambulatory blood pressure (ABP), predominantly during sleep, in a chronic obstructive pulmonary disease (COPD) patient with masked nocturnal hypertension. This is the first case demonstrating that a bronchodilator significantly lowered ABP in a COPD patient with hypertension. This case suggests that bronchodilator therapy may have potential as a new antihypertensive strategy targeting the lung in hypertensive patients with impaired lung function. This “bronchoantihypertensive” therapy seems to be more effective for reducing sleep blood pressure in hypertensive patients with COPD and sleep hypoventilatory/hypoxemic syndromes.
Similar content being viewed by others
Article PDF
References
Le Jemtel TH, Padeletti M, Jelic S : Diagnostic and therapeutic challenges in patients with coexistent chronic obstructive pulmonary disease and chronic heart failure. J Am Coll Cardiol 2007; 49: 171–180.
Goldberg RJ, Ciampa J, Lessard D, Meyer TE, Spencer FA : Long-term survival after heart failure: a contemporary population-based perspective. Arch Intern Med 2007; 167: 490–496.
Salisbury AC, Reid KJ, Spertus JA : Impact of chronic obstructive pulmonary disease on post-myocardial infarction outcomes. Am J Cardiol 2007; 99: 636–641.
Engström G, Wollmer P, Valind S, Hedblad B, Janzon L : Blood pressure increase between 55 and 68 years of age is inversely related to lung function: longitudinal results from the cohort study ‘Men born in 1914.’ J Hypertens 2001; 19: 1203–1208.
ZuWallack AR, ZuWallack RL : Tiotropium bromide, a new, once-daily inhaled anticholinergic bronchodilator for chronic-obstructive pulmonary disease. Expert Opin Pharmacother 2004; 5: 1827–1835.
Casey KR, Cantillo KO, Brown LK : Sleep-related hypoventilation/hypoxemic syndromes. Chest 2007; 131: 1936–1948.
Henriksen JH, Christensen NJ, Kok-Jensen A, Christiansen I : Increased plasma noradrenaline concentration in patients with chronic obstructive lung disease: relation to haemodynamics and blood gases. Scand J Clin Lab Invest 1980; 40: 419–427.
Heindl S, Lehnert M, Criee CP, Hasenfuss G, Andreas S : Marked sympathetic activation in patients with chronic respiratory failure. Am J Respir Crit Care Med 2001; 164: 597–601.
Bradley TD, Floras JS : Sleep apnea and heart failure: Part I: obstructive sleep apnea. Circulation 2003; 107: 1671–1678.
Haas DC, Foster GL, Nieto FJ, et al: Age-dependent associations between sleep-disordered breathing and hypertension: importance of discriminating between systolic/diastolic hypertension and isolated systolic hypertension in the Sleep Heart Health Study. Circulation 2005; 111: 614–621.
Shirasaki O, Yamashita S, Kawara S, et al: A new technique for detecting sleep apnea–related “midnight” surge of blood pressure. Hypertens Res 2006; 29: 695–702.
Cui R, Tanigawa T, Sakurai S, Yamagishi K, Iso H : Relationships between sleep-disordered breathing and blood pressure and excessive daytime sleepiness among truck drivers. Hypertens Res 2006; 29: 605–610.
Kario K, Schwartz JE, Pickering TG : Ambulatory physical activity as a determinant of diurnal blood pressure variation. Hypertension 1999; 34: 685–691.
Hoshide S, Ishikawa J, Eguchi K, Ojima T, Shimada K, Kario K : Masked nocturnal hypertension and target organ damage in hypertensives with well controlled self-measured home blood pressure. Hypertens Res 2007; 30: 143–149.
Kario K, Pickering TG, Matsuo T, Hoshide S, Schwartz JE, Shimada K : Stroke prognosis and abnormal nocturnal blood pressure falls in older hypertensives. Hypertension 2001; 38: 852–857.
Kario K, Shimada K : Risers and extreme-dippers of nocturnal blood pressure in hypertension: antihypertensive strategy for nocturnal blood pressure. Clin Exp Hypertens 2004; 26: 177–189.
Ingelsson E, Bjorklund-Bodegard K, Lind L, Arnlov J, Sundstrom J : Diurnal blood pressure pattern and risk of congestive heart failure. JAMA 2006; 295: 2859–2866.
Hoshide S, Kario K, Hoshide Y, et al: Associations between nondipping of nocturnal blood pressure decrease and cardiovascular target organ damage in strictly selected community-dwelling normotensives. Am J Hypertens 2003; 16: 434–438.
Curkendall SM, Lanes S, de Luise C, et al: Chronic obstructive pulmonary disease severity and cardiovascular outcomes. Eur J Epidemiol 2006; 21: 803–813.
Kato M, Komamura K, Kitakaze M : Tiotropium, a novel muscarinic M3 receptor antagonist, improved symptoms of chronic obstructive pulmonary disease complicated by chronic heart failure. Circ J 2006; 70: 1658–1660.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Kario, K., Uno, H. & Shimada, K. Sleep-Predominant Lowering of Ambulatory Blood Pressure by Bedtime Inhalation of a Novel Muscarinic M3 Receptor Antagonist: A New “Bronchoantihypertensive” Strategy Targeting the Lung in Hypertension with Chronic Obstructive Pulmonary Disease. Hypertens Res 31, 817–821 (2008). https://doi.org/10.1291/hypres.31.817
Received:
Accepted:
Issue Date:
DOI: https://doi.org/10.1291/hypres.31.817
Keywords
This article is cited by
-
Chronic kidney disease and premature ageing
Nature Reviews Nephrology (2014)